hrd in ovarian cancer: defined today, evolving for the future
Published 4 years ago • 178 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
45:27
what is hrd (homologous recombination deficiency) and how does it impact ovarian cancer?
-
29:07
actg dinner symposium highlights | beyond brca testing – does hrd matter? | prof michael friedlander
-
3:46
illumina oncology - homologous recombination deficiency (hrd) testing in ovarian cancer
-
12:05
the rationale for hrd genomic instability testing in patients with advanced ovarian cancer
-
8:41
impact of hrd status on frontline treatment of ovarian cancer
-
59:08
hrd testing in ovarian cancer - what do you need to consider?
-
2:39
testing for brca and hrd in ovarian cancer
-
1:04:52
practice-changing updates in ovarian cancer: implications for pathways construction
-
56:26
ask the experts: hrd and genetics
-
2:01:14
act genomics dinner symposium | moving from brca1/2 to hrd: beyond woman’s cancers
-
0:52
the importance of hrd testing in ovarian cancer
-
1:22
dr. bobbie j. rimel on genetic testing in ovarian cancer
-
6:08
treating ovarian cancer based on hrd status
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
3:46
introduction to homologous recombination deficiency (hrd) assessment
-
1:15
the influence of hrd testing in precision medicine
-
1:21
evaluating the interchangeability of hrd testing in ovarian cancer
-
2:05
hrd testing in ovarian cancer